June 23, 2017
It’s time to exhale and stop toking …
It's detremental to your health
Always a contrarian as I feel the pain of past wounds when anxiety builds
Pre-open indication: eight (8), 4 BUY and 4 SELLS
A critical indication ahead of “our” universe’s open!
Are you a subscriber? If not – you’re missing the realities of “our” universe!
June 1, 2017
Calling out the recent 10-Q page 17’s paragraph re a 24 page legal filing - this is what BSTG did NOT want investors to know or read!
May 31, 2017
CYTX jumps +$0.04 or +4.08% to $1.01 with 113.05 shares traded – it’s still ONLY an OPTION - something is better than ... nothing!
January 28, 2017
What difference does a $1.00 subscription a day, $100.00 a quarter abating the lack of a portfolio ... enema!
June 23, 2017
It’s tough to knock the sector down as the IBB jumps +0.20%, The XBI +1.40% as the XLV dives -0.15% with the VIX -4.39% while the …
Russell index is rebalancing for the next year in a year marked by record-setting moves for U.S. equities
The impact of the Russell rebalance is likely to be felt in the final fleeting seconds, or fractions of seconds, as the market closes Friday, and as funds that track the Russell change their composition to reflect the rebalancing, which takes hold on Monday.
Pre-open indications re-cap: 6 hit and 2 miss
Out and about: Stemline Therapeutics (STML +$0.60) presents SL-401 updated Stage 1 and 2 Data from ongoing pivotal trial in BPDCN and safety experience across multiple indications at EHA
I answer one question, in which company should investors commit and keep their money.
What have you missed, Friday’s results have implications to Monday's sector activity.
June 20, 2017
SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 SGMO prices 10 M shares at $7.25
June 13, 2017
AST is UP +$0.25 or +7.94% in the pre-market
June 12, 2017
FCSC is up +$0.23 or +9.27% in the pre-market, it's a BUY with an exit defined in short timing ... news has a life cycle in this market
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.